

# Steroid Treatment Trial in JIA (STAR-JIA): A randomised trial to compare the effectiveness, safety and cost-effectiveness of intravenous versus oral corticosteroid induction regimens for children and young people with juvenile idiopathic arthritis

<b>Submission date</b> 15/07/2023	<b>Recruitment status</b> Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 08/09/2023	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 04/02/2026	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

The aim of this study is to compare two different steroid treatments in children and young people with new-onset polyarticular juvenile idiopathic arthritis (JIA) to find out which is best. Medications used in the long-term management of JIA take around 12 weeks to start working. Steroids act quickly, reducing inflammation whilst the other medications start to work but have many potential side effects. There is a lack of evidence to suggest whether intravenous steroids or oral steroids are more effective, safe, tolerable for patients and which have a greater impact on quality of life.

### Who can participate?

Patients aged 1-18 years of age with at least five inflamed joints and newly diagnosed polyarticular JIA

### What does the study involve?

They will be randomly allocated to either a 6-week course (reducing dose regimen) of prednisolone liquid or tablets, taken at home OR a 3-day course of intravenous methylprednisolone on a hospital day-case unit. Participants will be assessed before starting treatment (baseline) and four follow-up visits at 6, 12, 24 and 52 weeks, in line with standard care appointments. Study visits will include assessments in standard care however, additional study-specific assessments will include reporting of side effects, and steroid toxicity risk including extra blood tests, questionnaires relating to the impact of JIA and treatment on quality of life and cost. The study offers an option for participants to donate blood samples for storage in a biobank for future research. Samples will not be analysed as part of the study but adopted by Liverpool University Biobank.

What are the possible benefits and risks of participating?

The direct burden on participation will be minimal as all research visits have been scheduled at the same time as standard-of-care visits to minimise the burden to participants. Research blood samples are taken at the same time as standard-of-care bloods to reduce burden.

Participants will be asked to complete several questionnaires which will prolong their clinic appointments. Once complete the questionnaire will be handed to the research team.

Risks associated with being treated with steroids (the IMP and the comparator) via different routes for JIA with the IMP, These risks are stated in the trial information sheets and site teams are appropriately trained as both routes of administration are used as standard of care.

All of the above risks are minimized with appropriate training and following policies and procedures by hospital Trusts and as stated in the protocol. For participants receiving oral prednisolone from hospital pharmacies, the pharmacy will dispense the drug as prescribed with appropriate guidance for taking it. For participants receiving IV methylprednisolone over 3 days on a hospital day unit, nurses who normally work on the day unit and have been appropriately trained to give IV methylprednisolone will be responsible for administering the drug and monitoring participants. It will not be given by Research Nurses who may be less familiar with the administration of this drug and do not usually administer this drug. This will minimize the risk of drug preparation, administration and monitoring errors.

Where is the study run from?

Alder Hey Children's NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

July 2023 to July 2028

Who is funding the study?

Health Technology Assessment Programme (UK)

Who is the main contact?

star-jia@liverpool.ac.uk

## Contact information

### Type(s)

Scientific, Public

### Contact name

Miss Laura Whitty

### ORCID ID

<https://orcid.org/0000-0003-3114-0877>

### Contact details

Liverpool Clinical Trials Centre

Block C

Waterhouse Building

Brownlow Street

Liverpool

United Kingdom

L69 3GL  
+44 (0)151 7940619  
star-jia@liverpool.ac.uk

### **Type(s)**

Principal investigator

### **Contact name**

Dr Clare Pain

### **Contact details**

Eaton Road  
Liverpool  
United Kingdom  
L12 2AP  
+44 (0)151 2284811  
Clare.Pain@alderhey.nhs.uk

## **Additional identifiers**

### **Integrated Research Application System (IRAS)**

1007610

### **Central Portfolio Management System (CPMS)**

58347

### **Protocol serial number**

AH23-05-006

## **Study information**

### **Scientific Title**

Steroid Treatment Trial in JIA (STAR-JIA): A randomised trial to compare the effectiveness, safety and cost-effectiveness of intravenous versus oral corticosteroid induction regimens for children and young people with juvenile idiopathic arthritis

### **Acronym**

STAR-JIA

### **Study objectives**

Primary objectives:

To compare the clinical effectiveness of intravenous methylprednisolone versus oral prednisolone for controlling new-onset polyarticular juvenile idiopathic arthritis (JIA) in JIA Core Outcomes.

Secondary objectives:

1. To compare the differences in JIA Core Outcomes for intravenous methylprednisolone versus oral prednisolone for the following domains:

1.1. Pain

1.2. Function

### 1.3. Health-related Quality of Life (HRQOL)

2. To assess the effectiveness of intravenous versus oral corticosteroids in minimising the need for additional treatments including all corticosteroid routes and additional disease-modifying anti-rheumatic drugs (DMARDs)/biologics.

3. To evaluate short/medium-term safety and tolerability of IV versus oral corticosteroids, with regards to adverse reactions, serious adverse events, laboratory assessments and paediatric glucocorticoid toxicity index (pGTI).

4. To determine if a dose-response relationship can be identified in the efficacy/adverse responses to corticosteroids across all participants by secondary analysis, normalising corticosteroids received for dose, bioavailability and potency using previously published data.

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

Approved 08/09/2023, Yorkshire and the Humber - Leeds East (NHSBT Newcastle Blood Donor Centre, Holland Drive, Newcastle-upon-Tyne, NE2 4NQ, United Kingdom; +44 (0)207 1048171, (0) 207 104 8141; leedseast.rec@hra.nhs.uk), ref: 23/YH/0173

### **Primary study design**

Interventional

### **Study design**

Open randomized controlled parallel-group trial

### **Study type(s)**

Efficacy, Safety, Treatment

### **Health condition(s) or problem(s) studied**

Juvenile idiopathic arthritis (polyarticular)

### **Interventions**

IMP: Intravenous methylprednisolone administered over 3 days on a hospital day unit

Comparator: Oral prednisolone taken/administered over 6 weeks at home

The doses, frequency and method of administration of the IMP and comparator drug are provided below.

IMP: Methylprednisolone

Route: Intravenous administration

Form: Powder for injection to be prepared for intravenous administration

30 mg/kg per day for 3 consecutive days (Maximum dose: 1g per day)

Comparator: Prednisolone

Route: Oral administration

Form: Tablet or solution

The initial dose of prednisolone will be 1 mg/kg per day with a maximum dose of 40 mg. For participants weighing  $\geq 40$  kg, the weaning will be a reduction in line with the percentage decrease used for lighter patients.

Week of oral prednisolone 1: Dose (patient <40 kg): 1 mg/kg per day; Dose (patient ≥40 kg): 40 mg  
Week of oral prednisolone 2: Dose (patient <40 kg): 0.75 mg/kg per day; Dose (patient ≥40 kg): 30 mg  
Week of oral prednisolone 3: Dose (patient <40 kg): 0.5 mg/kg per day; Dose (patient ≥40 kg): 20 mg  
Week of oral prednisolone 4: Dose (patient <40 kg): 0.375 mg/kg per day; Dose (patient ≥40 kg): 15 mg  
Week of oral prednisolone 5: Dose (patient <40 kg): 0.25 mg/kg per day; Dose (patient ≥40 kg): 10 mg  
Week of oral prednisolone 6: Dose (patient <40 kg): 0.125 mg/kg per day; Dose (patient ≥40 kg): 5 mg

## **Intervention Type**

Drug

## **Phase**

Phase IV

## **Drug/device/biological/vaccine name(s)**

Methylprednisolone, prednisolone

## **Primary outcome(s)**

Primary clinical outcome:

Disease activity measured using the JADAS10 score at 0 weeks (Baseline) and 6 weeks

Primary economic outcomes:

1. Incremental cost per quality-adjusted life year (QALY) gained measured using Resource Use Questionnaires and Patient Level Information and Costing System (PLICS) data at 0 weeks (Baseline), 6 weeks, 12 weeks, 24 weeks and 52 weeks.
2. Resource use, costs and health utilities associated with IV and oral corticosteroids measured using Resource Use Questionnaires and Patient Level Information and Costing System (PLICS) data at 0 weeks (Baseline), 6 weeks, 12 weeks, 24 weeks and 52 weeks.

## **Key secondary outcome(s)**

1. Disease activity in subjects with polyarticular Juvenile Idiopathic Arthritis (JIA) randomised to IV methylprednisolone or oral prednisolone measured using the American College of Rheumatology (ACR) Pediatric Response Criteria (30, 50, 70, 90, 100) at 0 weeks (baseline), 6 weeks, 12 weeks, 24 weeks, 52 weeks.
2. Disease activity in subjects with polyarticular Juvenile Idiopathic Arthritis (JIA), randomised to IV methylprednisolone or oral prednisolone measured using the JADAS (10,27,71) at 0 weeks (baseline), 6 weeks, 12 weeks, 24 weeks, 52 weeks.
3. Disease activity in subjects with polyarticular Juvenile Idiopathic Arthritis (JIA) randomised to IV methylprednisolone or oral prednisolone measured by JADAS10 cut-off scores at 0 weeks (baseline), 6 weeks, 12 weeks, 24 weeks, 52 weeks.
4. Pain in subjects with polyarticular Juvenile Idiopathic Arthritis (JIA) randomised to IV methylprednisolone or oral prednisolone measured using the Pain Visual Analogue Scale (Pain VAS) at 0 weeks (baseline), 6 weeks, 12 weeks, 24 weeks, 52 weeks.
5. Function in subjects with polyarticular Juvenile Idiopathic Arthritis (JIA) randomised to IV methylprednisolone or oral prednisolone measured using the Childhood Health Assessment

Questionnaire (CHAQ) at 0 weeks (baseline), 6 weeks, 12 weeks, 24 weeks, 52 weeks.

6. Health-related Quality of Life (HRQoL) in subjects with polyarticular Juvenile Idiopathic Arthritis (JIA) randomised to IV methylprednisolone or oral prednisolone measured using Child Health Utility 9D Questionnaire (CHU-9D) and CAPTURE-JIA PROM at 0 weeks (baseline), 6 weeks, 12 weeks, 24 weeks, 52 weeks.

7. Requirement for additional treatment for subjects with polyarticular Juvenile Idiopathic Arthritis (JIA) due to failure to respond to IV methylprednisolone or oral prednisolone measured using concomitant medications recorded at 6 weeks, 12 weeks, 24 weeks, 52 weeks.

8. Glucocorticoid toxicity in subjects with polyarticular Juvenile Idiopathic Arthritis (JIA) randomised to IV methylprednisolone or oral prednisolone measured using Paediatric Glucocorticoid Toxicity Index (pGTI) scores at 0 weeks (baseline), 6 weeks, 12 weeks, 24 weeks, 52 weeks

### **Completion date**

31/07/2028

## **Eligibility**

### **Key inclusion criteria**

1. Participants must be between 1-18 years of age inclusive
2. New onset pcJIA diagnosed by a paediatric rheumatologist (to include polyarticular rheumatoid factor (RF+) positive, polyarticular RF negative, enthesitis-related arthritis, psoriatic arthritis and extended oligo-articular). This includes new diagnosis of JIA with at least 5 joints affected and patients previously categorised as oligoarticular JIA (with 4 joints or less) who have extended to at least 5 joints.
3. Participants are expected to be able to commence allocated treatment within 1 week of randomisation
4. Written, informed consent and where appropriate, assent obtained from participant or their legal representative
5. Participants of child-bearing potential must be willing to abstain from sexual intercourse from consent to their final visit and/or use another acceptable contraception method as described in section 9.10.5 of this protocol

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

1 Years

### **Upper age limit**

18 Years

### **Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Any contraindication to starting corticosteroids
2. Any contraindication to starting methotrexate
3. Pregnancy
4. Treatment with systemic corticosteroids within 4 weeks preceding screening (includes IV, IA, IM and oral)
5. Treatment with methotrexate within 12 weeks preceding screening
6. Any co-morbidity which in view of the treating clinician makes participation inappropriate

**Date of first enrolment**

05/03/2024

**Date of final enrolment**

06/02/2027

**Locations****Countries of recruitment**

United Kingdom

England

Northern Ireland

Wales

**Study participating centre****Alder Hey Hospital**

Eaton Road  
West Derby  
Liverpool  
England  
L12 2AP

**Study participating centre****University College London Hospitals NHS Foundation Trust**

250 Euston Road  
London  
England  
NW1 2PG

**Study participating centre**

**University Hospitals Bristol and Weston NHS Foundation Trust**

Trust Headquarters  
Marlborough Street  
Bristol  
England  
BS1 3NU

**Study participating centre**

**University Hospitals Sussex NHS Foundation Trust**

Worthing Hospital  
Lyndhurst Road  
Worthing  
England  
BN11 2DH

**Study participating centre**

**Noahs Ark Childrens Hospital for Wales**

Cardiff & Vale University Health Bd  
Heath Park  
Cardiff  
Wales  
CF14 4XW

**Study participating centre**

**John Radcliffe Hospital**

Headley Way  
Headington  
Oxford  
England  
OX3 9DU

**Study participating centre**

**Royal Preston Hospital**

Sharoe Green Lane  
Fulwood  
Preston  
England  
PR2 9HT

**Study participating centre**

**Norfolk and Norwich Hospital**

Colney Lane  
Colney  
Norwich  
England  
NR4 7UY

**Study participating centre**

**Freeman Road Hospital**

Freeman Road  
High Heaton  
Newcastle upon Tyne  
England  
NE7 7DN

**Study participating centre**

**New Cross Hospital**

Wolverhampton Road  
Heath Town  
Wolverhampton  
England  
WV10 0QP

**Study participating centre**

**Bradford Royal Infirmary**

Chesnut House  
Duckworth Lane  
Bradford  
England  
BD9 6RJ

**Study participating centre**

**Royal Stoke University Hospital**

Newcastle Road  
Stoke-on-trent  
England  
ST4 6QG

**Study participating centre**

**Manchester Royal Infirmary**

Oxford Road

Manchester  
England  
M13 9WL

**Study participating centre**  
**Great Ormond Street Hospital for Children**  
Great Ormond Street  
London  
England  
WC1N 3JH

**Study participating centre**  
**Northern General Hospital**  
Northern General Hospital NHS Trust  
C Floor, Huntsman Building  
Herries Road  
Sheffield  
England  
S5 7AU

**Study participating centre**  
**Addenbrooke's Hospital**  
Hills Road  
Cambridge  
England  
CB2 0QQ

**Study participating centre**  
**Cheltenham General Hospital**  
Sandford Road  
Cheltenham  
England  
GL53 7AN

**Study participating centre**  
**Queens Medical Centre**  
Nottingham University Hospital  
Derby Road  
Nottingham  
England  
NG7 2UH

**Study participating centre**  
**Guy's and St Thomas' NHS Foundation Trust**  
St Thomas' Hospital  
Westminster Bridge Road  
London  
England  
SE1 7EH

**Study participating centre**  
**Leicester Royal Infirmary**  
Infirmary Square  
Leicester  
England  
LE1 5WW

## Sponsor information

**Organisation**  
Alder Hey Children's NHS Foundation Trust

**ROR**  
<https://ror.org/00p18zw56>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
Health Technology Assessment Programme

**Alternative Name(s)**  
NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be made available on request from Liverpool Clinical Trials Centre, star-jia@liverpool.ac.uk.

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes